Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... In ... a mother and divorcee, shares her enthusiasm for Botox and lip injections, which she ... world famous youth oriented Coachella Valley Music and Arts Festival. The article explains that ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Conditions were ... at Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures ... nearly $33,000. , The 5k Run and Walk and 1-mile walk were ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology: